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ALL-CAUSE AND DISEASE-SPECIFIC HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH VENOUS THROMBOEMBOLISM IN COMMERCIAL, MEDICARE AND MEDICAID BENEFICIARIES
OBJECTIVES:
To describe the real-world clinical complications associated with venous thromboembolism (VTE) and quantify the incremental direct all-cause and disease-specific health care utilization and costs associated with VTE. METHODS: Health insurance claims between January 2004 and December 2008 from the IMPACT database were used. Adult patients with an index VTE diagnosis (deep vein thrombosis [DVT] , pulmonary embolism [PE], or both) were matched 1:1 with control patients without VTE. Each patient's observation period began on the date of the index VTE or corresponding date for controls and ended on the earlier of 1 year after the study index date, the health plan disenrollment date, or December 31, 2008. The proportion of patients with recurrent VTE requiring hospitalization or post-thrombotic syndrome (PTS) was calculated. All-cause incremental health care costs associated with VTE and disease-specific costs related to VTE complications were also reported. RESULTS: The VTE and no-VTE cohorts (16,969 subjects in each group) were well matched for age, gender, comorbidities, and VTE risk factors. The index VTE event was DVT, PE, or both in 12,711, 2473, and 1785 patients, respectively. The risks of recurrent VTE requiring hospitalization and PTS during the 1-year follow-up period were 3.6% and 6.2%, respectively. Patients with VTE had significantly higher average yearly all-cause costs compared to no-VTE patients (mean [SD] : $33,531 [$70,393] versus $17,590 [$42,011] , cost differenceϭ$15,941; 95% CIϭ14,819 -17,012). Disease-specific health care costs related to VTE complications represented 18.3% ($2913 of $15,941) of the all-cause cost difference between the two groups. CONCLUSIONS: In this large matched-cohort study, VTE was associated with a 3.6% risk of hospitalization due to recurrence and a 6.2% risk of PTS at 1 year. VTE was also associated with significant health care cost burden-diseasespecific costs related to VTE complications represented nearly one-fifth of the incremental all-cause costs associated with VTE. 
PCV37 BURDEN OF ATRIAL FIBRILLATION RELATED STROKE IN CHINA
OBJECTIVES:
To estimate the 1-year direct and indirect costs of ischemic stroke in Chinese patients with atrial fibrillation (AF). METHODS: A cost-of-illness study was conducted through hospital chart review and a patient follow up survey. Costs were estimated from the societal perspective. Three hundred hospital charts from 12 tier-3 hospitals and 6 tier-2 hospitals in 6 cities across China were randomly selected and reviewed for cost of stroke during hospitalization from patients discharged from January, 2009 to December, 2010 (discharge diagnosis of both, ischemic stroke and AF). Of those, 50 patients were followed up to collect the long-term direct and indirect costs related to ischemic stroke in the year following discharge. RESULTS: We report here results from two hospitals (Nϭ30): patients had a mean age of 75 years and mean length of stay of 16 days (95%CIϭ [14, 19] ). Females accounted for 43%. The mean time interval between stroke onset and hospitalization was 24 hours (95%CIϭ [14, 33] ). The cohort scored on average 3 points (95%CIϭ [2, 4]) on the CHA2DS2-VASc, indicating a high risk of stroke considering patient demographics and disease history. Average total 1-year costs of stroke management were estimated at 19,560.01 RMB (2010 costs; 4951.90 US$), almost all of which was attributable to direct costs. Costs of inpatient care dominated direct costs, representing 90.3% of the total direct costs. Average total costs during hospitalization were estimated at 17,659.31 RMB (95%CIϭ [13,538.39, 21,780 .23]), 62.5% of which was attributable to medication. CONCLUSIONS: The findings indicate that ischemic stroke among AF patients are associated with high direct costs, imposing a considerable burden on society. Hospital costs are the predominant contributor, consistent with the current pattern of care in China, where patient care is usually provided via hospitals. 
PCV38 VENOUS THROMBOEMBOLISM: A REFINED UNITED STATES COST MODEL WITH LONG TERM ATTACK RATES
OBJECTIVES: To develop United States (US) cost model estimates for venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Total US costs were calculated as well as hospital-acquired, "preventable", and indirect VTE costs. METHODS: A literature review was performed to determine VTE incidences, morbidity probabilities, case-fatality rates, and direct medical and indirect costs. Indirect costs were derived from present value of lifetime earnings (PVLE) due to premature death. Two decision trees mapping PE and DVT outcomes were developed, and cost models were constructed in Microsoft Excel. The decision trees first contain primary VTE characteristics and outcomes: hospital-or community-acquired; fatal versus non-fatal; readmission/recurrence versus none; and instant versus non-instant death. Initially surviving patients are at risk for associated morbidities: minor bleed; major bleed; heparin induced thrombocytopenia; chronic thromboembolic pulmonary hypertension; postthrombotic syndrome; and resolution or no resolution of symptoms or death. The average patient's cost, the sum of each decision tree pathway's probabilityweighted cost, were multiplied by low and high annual PE and DVT incident events to determine total cost ranges. All costs were adjusted to 2011 US dollars. Two multi-way sensitivity analyses were conducted: one analysis has higher probabilities and costs; the second introduces long term attack rates (LTAR), pooled incident and recurrent events, into the baseline and first multi-way sensitivity analyses with only low VTE incidences. RESULTS: Annual US total base case (LTAR sensitivity analysis), hospital-acquired, preventable, and indirect VTE costs range from $13. 4-27.0 ($15.3-34.3) billion, $8.9-18.0 ($10.2-25. 3) billion, $4.5-14.0 ($5.1-12.7) billion, and $4.5-9.8 ($5.6-11.7) billion, respectively. PE comprises the majority of VTE costs. Indirect costs due to PVLE represent at least 33% of total VTE costs. CONCLUSIONS: The United States could avoid substantial costs, morbidity and mortality if effective VTE prophylactic strategies were implemented. This attainable goal would contribute to important health care reform. 
PCV39 DETERMINANTS OF PHARMACEUTICAL EXPENDITURES FOR PATIENTS WITH HYPERTENSION
